Vor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M

Reuters03-30

Vor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M

Vor Bio posted net income of USD 1.7 billion for fourth-quarter 2025, swinging from a year-earlier net loss on a gain from changes in fair value of liability-classified warrants.
Full-year net loss widened to USD 700 million, driven by a loss on warrant fair-value changes and the telitacicept license purchase.
R&D expense fell to USD 19 million in the quarter, while G&A expense climbed to USD 17 million.
Pro-forma cash and investments totaled USD 530 million at Dec. 31, 2025, including USD 75 million gross proceeds from a March 2026 private placement.
Enrollment began in the UPSTREAM SjD Phase 3 trial with first patient dosed, while UPSTREAM MG Phase 3 enrollment continues with topline data expected in 1H 2027 and cash runway projected into early 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300801PRIMZONEFULLFEED9680193) on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623175693?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623175693","market":"fut","top_or_hot":-1,"title":"Vor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Vor Bio posted net income of USD 1.7 billion for fourth-quarter 2025, swinging from a year-earlier net loss on a gain from changes in fair value of liability-classified warrants.\n        </li>\n<li>\n          Full-year net loss widened to USD 700 million, driven by a loss on warrant fair-value changes and the telitacicept license purchase.\n        </li>\n<li>\n          R&amp;D expense fell to USD 19 million in the quarter, while G&amp;A expense climbed to USD 17 million.\n        </li>\n<li>\n          Pro-forma cash and investments totaled USD 530 million at Dec. 31, 2025, including USD 75 million gross proceeds from a March 2026 private placement.\n        </li>\n<li>\n          Enrollment began in the UPSTREAM SjD Phase 3 trial with first patient dosed, while UPSTREAM MG Phase 3 enrollment continues with topline data expected in 1H 2027 and cash runway projected into early 2029.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VOR\">Vor Biopharma Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300801PRIMZONEFULLFEED9680193) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Vor Bio posted net income of USD 1.7 billion for fourth-quarter 2025, swinging from a year-earlier net loss on a gain from changes in fair value of liability-classified warrants.\n        </li>\n<li>\n          Full-year net loss widened to USD 700 million, driven by a loss on warrant fair-value changes and the telitacicept license purchase.\n        </li>\n<li>\n          R&amp;D expense fell to USD 19 million in the quarter, while G&amp;A expense climbed to USD 17 million.\n        </li>\n<li>\n          Pro-forma cash and investments totaled USD 530 million at Dec. 31, 2025, including USD 75 million gross proceeds from a March 2026 private placement.\n        </li>\n<li>\n          Enrollment began in the UPSTREAM SjD Phase 3 trial with first patient dosed, while UPSTREAM MG Phase 3 enrollment continues with topline data expected in 1H 2027 and cash runway projected into early 2029.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VOR\">Vor Biopharma Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300801PRIMZONEFULLFEED9680193) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL9XfMkh:1","article_id":"2623175693","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623175693","pubTimestamp":1774872463,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vor Bio posted net income of USD 1.7 billion for fourth-quarter 2025, swinging from a year-earlier net loss on a gain from changes in fair value of liability-classified warrants.Full-year net loss widened to USD 700 million, driven by a loss on warrant fair-value changes and the telitacicept license purchase.R&D expense fell to USD 19 million in the quarter, while G&A expense climbed to USD 17 million.Pro-forma cash and investments totaled USD 530 million at Dec. 31, 2025, including USD 75 million gross proceeds from a March 2026 private placement.Enrollment began in the UPSTREAM SjD Phase 3 trial with first patient dosed, while UPSTREAM MG Phase 3 enrollment continues with topline data expected in 1H 2027 and cash runway projected into early 2029.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","VOR":"Vor Biopharma Inc.","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD"},"translate_title":"VOR Bio 2025财年第四季度净利润攀升至$1.7 B；预计现金增至5.3亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOR":0.9,"NDAQ":0.9},"content_text":"Vor Bio Q4 FY25 net income climbs to $1.7B; pro-forma cash rises to $530M\n    \n\n\n          Vor Bio posted net income of USD 1.7 billion for fourth-quarter 2025, swinging from a year-earlier net loss on a gain from changes in fair value of liability-classified warrants.\n        \n\n          Full-year net loss widened to USD 700 million, driven by a loss on warrant fair-value changes and the telitacicept license purchase.\n        \n\n          R&D expense fell to USD 19 million in the quarter, while G&A expense climbed to USD 17 million.\n        \n\n          Pro-forma cash and investments totaled USD 530 million at Dec. 31, 2025, including USD 75 million gross proceeds from a March 2026 private placement.\n        \n\n          Enrollment began in the UPSTREAM SjD Phase 3 trial with first patient dosed, while UPSTREAM MG Phase 3 enrollment continues with topline data expected in 1H 2027 and cash runway projected into early 2029.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300801PRIMZONEFULLFEED9680193) on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623175693","isCrawlerRequest":true}